贝伐珠单抗联合铂类药物化疗对晚期卵巢癌患者血清TGF-β1、MIF水平和预后的影响  

Effect of Bevacizumab Combined with Platinum-based Chemotherapy on Serum TGF-β1 and MIF Levels and the Prognosis of Patients with Advanced Ovarian Cancer

作　　者：王英[1] 徐燕 王娜[1] 孙勃[1] 郭华[2] WANG Ying;XU Yan;WANG Na(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院,473000 [2]郑州大学第三附属医院,450000

出　　处：《实用癌症杂志》2024年第9期1465-1468,共4页The Practical Journal of Cancer

基　　金：2020年度河南省医学科技攻关计划项目(编号:LHGJ20200463)。

摘　　要：目的研究贝伐珠单抗联合铂类药物化疗对晚期卵巢癌患者血清中TGF-β1、MIF水平和预后的影响。方法选取68例晚期卵巢癌患者,按照随机数字表法分为2组,各34例。对照组采用标准一线化疗方案,21天为1个周期,治疗6个周期。试验组在化疗进行的基础上同时联合靶向药物,标准一线化疗方案与对照组一致,化疗后贝伐珠单抗单独用药,继续维持治疗12个周期。比较2组患者的治疗效果、转化生长因子β1(TGF-β1)、巨噬细胞移动抑制因子(MIF)水平、不良反应以及预后生存情况。结果治疗后,2组患者客观缓解率(ORR)差异无统计学意义(P>0.05),试验组疾病控制率(DCR)高于对照组(P<0.05)。治疗后,2组患者的TGF-β1、MIF均降低(P<0.05),且试验组低于对照组(P<0.05)。2组患者在治疗期间腹痛腹泻、恶心呕吐、骨髓抑制、消化道反应等不良反应发生率差异无统计学意义(P>0.05)。随访12个月,试验组复发转移率(23.55%)、死亡率(8.82%)均显著低于对照组(47.06%、29.41%),差异有统计学意义(χ^(2)=4.121、4.660,P=0.042、0.031)。结论贝伐珠单抗联合铂类药物可以提高晚期卵巢癌患者临床疗效,下调血清肿瘤标志物TGF-β1、MIF水平,在不增加不良反应的同时保持良好的预后生存率。Objective To explore the effect of bevacizumab combined with platinum-based chemotherapy on serum transforming growth factorβ1(TGF-β1)and macrophage migration inhibitory factor(MIF)levels and the prognosis of patients with advanced ovarian cancer.Methods A total of 68 patients with advanced ovarian cancer were selected,and divided into 2 groups according to the random number table method,with 34 patients in each group.The control group was treated with standard first-line chemotherapy(21 days as a cycle,6 cycles in total).The treatment group was treated with targeted drugs on the basis of chemotherapy.The standard first-line chemotherapy regimen was the same as that of the control group.After chemotherapy,the treatment group was treated with bevacizumab alone for 12 cycles.Therapeutic effect,TGF-β1 and MIF levels,adverse reactions,and the prognosis were compared between groups.Results There was no statistically significant difference in the objective remission rate(ORR)between groups after treatment(P>0.05).The disease control rate(DCR)in the treatment group was higher than that in the control group(P<0.05).After treatment,TGF-β1 and MIF levels in the 2 groups decreased(P<0.05),and the levels in treatment group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence rates of adverse reactions such as abdominal pain,diarrhea,nausea and vomiting,bone marrow suppression and digestive tract reactions between groups(P>0.05).12 months of follow-up found that the recurrence and metastasis rate(23.55%)and mortality rate(8.82%)in the treatment group were significantly lower than those in the control group(47.06%and 29.41%)(χ^(2)=4.121,4.660,P=0.042,0.031).Conclusion Bevacizumab combined with platinum drugs can improve the clinical effect in the treatment of patients with advanced ovarian cancer and down-regulate the serum tumor markers(TGF-β1 and MIF)levels,without increasing adverse reactions and with good prognosis.

关 键 词：晚期卵巢癌 贝伐珠单抗 铂类药物 转化生长因子Β1 不良反应 预后 

分 类 号：R737.31[医药卫生—肿瘤]